IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0157323.html
   My bibliography  Save this article

The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease

Author

Listed:
  • Benjamin O Yarnoff
  • Thomas J Hoerger
  • Siobhan A Simpson
  • Meda E Pavkov
  • Nilka R Burrows
  • Sundar S Shrestha
  • Desmond E Williams
  • Xiaohui Zhuo

Abstract

Background: Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating agents (ESAs) for managing chronic anemia in persons with chronic kidney disease (CKD), there are differences in the recommended hemoglobin (Hb) treatment target and no guidelines consider the costs or cost-effectiveness of treatment. In this study, we explored the most cost-effective Hb target for anemia treatment in persons with CKD stages 3–4. Methods and Findings: The CKD Health Policy Model was populated with a synthetic cohort of persons over age 30 with prevalent CKD stages 3–4 (i.e., not on dialysis) and anemia created from the 1999–2010 National Health and Nutrition Examination Survey. Incremental cost-effectiveness ratios (ICERs), computed as incremental cost divided by incremental quality adjusted life years (QALYs), were assessed for Hb targets of 10 g/dl to 13 g/dl at 0.5 g/dl increments. Targeting a Hb of 10 g/dl resulted in an ICER of $32,111 compared with no treatment and targeting a Hb of 10.5 g/dl resulted in an ICER of $32,475 compared with a Hb target of 10 g/dl. QALYs increased to 4.63 for a Hb target of 10 g/dl and to 4.75 for a target of 10.5 g/dl or 11 g/dl. Any treatment target above 11 g/dl increased medical costs and decreased QALYs. Conclusions: In persons over age 30 with CKD stages 3–4, anemia treatment is most cost-effective when targeting a Hb level of 10.5 g/dl. This study provides important information for framing guidelines related to treatment of anemia in persons with CKD.

Suggested Citation

  • Benjamin O Yarnoff & Thomas J Hoerger & Siobhan A Simpson & Meda E Pavkov & Nilka R Burrows & Sundar S Shrestha & Desmond E Williams & Xiaohui Zhuo, 2016. "The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-14, July.
    • Handle: RePEc:plo:pone00:0157323
    DOI: 10.1371/journal.pone.0157323
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157323
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0157323&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0157323?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Joel Tsevat & Lee Goldman & Jane R. Soukup & Gervasio A. Lamas & Kathleen F. Connors & Carole C. Chapin & Thomas H. Lee, 1993. "Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction," Medical Decision Making, , vol. 13(2), pages 161-165, June.
    2. Richard T. Meenan & Somnath Saha & Roger Chou & Karleen Swarztrauber & Kathryn Pyle Krages & Maureen C. O'Keeffe-Rosetti & Marian McDonagh & Benjamin K. S. Chan & Mark C. Hornbrook & Mark Helfand, 2007. "Cost-Effectiveness of Echocardiography to Identify Intracardiac Thrombus among Patients with First Stroke or Transient Ischemic Attack," Medical Decision Making, , vol. 27(2), pages 161-177, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson, 2007. "Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 25-30, March.
    2. Mason, J.E. & Denton, B.T. & Shah, N.D. & Smith, S.A., 2014. "Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 727-738.
    3. Gandjour, Afschin & Stock, Stephanie, 2007. "A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness," Health Policy, Elsevier, vol. 83(2-3), pages 257-267, October.
    4. William Hollingworth & Richard A. Deyo & Sean D. Sullivan & Scott S. Emerson & Darryl T. Gray & Jeffrey G. Jarvik, 2002. "The practicality and validity of directly elicited and SF‐36 derived health state preferences in patients with low back pain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 71-85, January.
    5. Zethraeus, Niklas & Borgström, Fredrik & Jönsson, Bengt & Kanis, John, 2004. "A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden – results based on the Women’s Health Initiative randomised controlled trial," SSE/EFI Working Paper Series in Economics and Finance 571, Stockholm School of Economics.
    6. J. Logman & Bart Heeg & Johan Herlitz & Ben Hout, 2010. "Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden," Applied Health Economics and Health Policy, Springer, vol. 8(4), pages 251-265, July.
    7. Afschin Gandjour, 2010. "A model to predict the cost‐effectiveness of disease management programs," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 697-715, June.
    8. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    9. Bart Heeg & Ron Peters & Marc Botteman & Ben Hout, 2007. "Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 25(9), pages 769-782, September.
    10. G. Ardine De Wit & Jan J.V. Busschbach & Frank Th. De Charro, 2000. "Sensitivity and perspective in the valuation of health status: whose values count?," Health Economics, John Wiley & Sons, Ltd., vol. 9(2), pages 109-126, March.
    11. Anna-Liesa Lange & Philipp Otto, 2016. "Bayes’sche Statistik in der Dienstleistungsforschung [Bayesian statistics in service research]," AStA Wirtschafts- und Sozialstatistisches Archiv, Springer;Deutsche Statistische Gesellschaft - German Statistical Society, vol. 10(4), pages 247-267, December.
    12. Paul Heidenreich & Mark B. McClellan, 2001. "Trends in Heart Attack Treatment and Outcomes, 1975-1995 -- Literature Review and Synthesis," NBER Chapters, in: Medical Care Output and Productivity, pages 363-410, National Bureau of Economic Research, Inc.
    13. Sharma, Rajiv & Stano, Miron, 2010. "Implications of an economic model of health states worse than dead," Journal of Health Economics, Elsevier, vol. 29(4), pages 536-540, July.
    14. Björn Stollenwerk & Afschin Gandjour & Markus Lüngen & Uwe Siebert, 2013. "Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 1035-1048, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0157323. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.